These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29025276)

  • 1. Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
    Fuller K; Malecki S; Anselmo L; Borrego ME; Jakeman B; Burnett A
    Ann Pharmacother; 2018 Mar; 52(3):257-262. PubMed ID: 29025276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
    Trujillo-Santos J; Bergmann JF; Bortoluzzi C; López-Reyes R; Giorgi-Pierfranceschi M; López-Sáez JB; Ferrazzi P; Bascuñana J; Suriñach JM; Monreal M
    J Thromb Haemost; 2017 Mar; 15(3):429-438. PubMed ID: 28120516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients.
    King AC; Ma MQ; Chisholm G; Toale KM
    J Oncol Pharm Pract; 2016 Apr; 22(2):265-70. PubMed ID: 25888639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3).
    Eriksson BI; Agnelli G; Gallus AS; Lassen MR; Prins MH; Renfurm RW; Kashiwa M; Turpie AG
    Thromb Haemost; 2014 Feb; 111(2):213-25. PubMed ID: 24136153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Fuji T; Ochi T; Niwa S; Fujita S
    J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily enoxaparin for outpatient treatment of acute venous thromboembolism: a case-control study.
    Hacobian M; Shetty R; Niles CM; Gerhard-Herman M; Vallurupalli N; Baroletti S; McKean SC; Sonis J; Parasuraman S; Kosowsky JM; Goldhaber SZ
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):21-5. PubMed ID: 19147527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
    Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR;
    J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
    Pannucci CJ; Fleming KI; Agarwal J; Rockwell WB; Prazak AM; Momeni A
    Plast Reconstr Surg; 2018 Jul; 142(1):239-249. PubMed ID: 29649055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
    Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
    Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.
    Suchkov IA; Martinez-Gonzalez J; Schellong SM; Garbade T; Falciani M;
    Clin Drug Investig; 2018 Feb; 38(2):181-189. PubMed ID: 29214507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
    Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
    Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.